Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › mFOLFOX6

mFOLFOX6

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of mFOLFOX6

7 trials tracked of mFOLFOX6: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 2934 citations.

7Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 5 Phase 1 1
  1. Phase 3 Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Completed · 2,934 cited
  2. Phase 2 Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma Completed
  3. Phase 2 A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy Completed
  4. Phase 2 Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer Completed
  5. Phase 2 PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors Completed
  6. Phase 2 A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors Completed
Show 1 more trials
  1. Phase 1 Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC
Oncology RCT
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC New Drug Order Doesn't Beat Old Standard
A phase III randomized controlled trial in 263 untreated, unresectable wild-type RAS/BRAF metastatic colorectal cancer patients found no dif…
A new drug order for advanced colon cancer did not improve disease control or survival compared to the standard treatment sequence.
Apr 16, 2026
Atezolizumab with mFOLFOX6 Boosts 3-Year DFS by 10.1% in Stage III dMMR Colon Cancer
Oncology RCT
Atezolizumab with mFOLFOX6 Boosts 3-Year DFS by 10.1% in Stage III dMMR Colon Cancer Could a New Treatment Boost Survival for Stage III Colon Cancer Patients?
In a phase 3 trial, atezolizumab plus mFOLFOX6 improved 3-year disease-free survival to 86.3% vs. 76.2% with mFOLFOX6 alone (HR 0.50; 95% CI…
Adding atezolizumab to standard chemotherapy boosted 3-year disease-free survival to 86% in stage III colon cancer patients, up from 76% wit…
Mar 27, 2026